PA5-14094

antibody from Invitrogen Antibodies

Targeting: PLK2 SNK

Western blot (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-14094

Provider

Invitrogen Antibodies

Product name

PLK2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Vial size

400 µL

Concentration

2 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib.

Yamashita Y, Morita S, Hosoi H, Kobata H, Kishimoto S, Ishibashi T, Mishima H, Kinoshita A, Backes BJ, Yoshiura KI, Papa FR, Sonoki T, Tamura S
International journal of molecular sciences 2020 Aug 31;21(17)

---

Opposing action of nuclear factor κB and Polo-like kinases determines a homeostatic end point for excitatory synaptic adaptation.

Mihalas AB, Araki Y, Huganir RL, Meffert MK
The Journal of neuroscience : the official journal of the Society for Neuroscience 2013 Oct 16;33(42):16490-501

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 6 PLK2 expression was IRE1alpha-dependent and its inhibitor exhibited anti-myeloma effects in IM-9 cells. PLK2 protein and mRNA were expressed strongly in patients with NDMM. ( A , B ) Quantitative RT-PCR of relative rat Plk1 and Plk2 mRNA levels in duplicate ( A ) and western blotting of PLK2 protein ( B ) from doxycycline (DOX)-inducible IRE1alpha-overexpressing INS-1 insulinoma cells treated with vehicle (DMSO) or 0.5 muM of KIRA8 with or without 1 mug/mL of DOX for 24 h. ( C ) Quantitative RT-PCR of the relative PLK1 and PLK2 mRNA levels from IM-9 cells treated with 25 muM of AMG for 24 h ( n = 3). ( D ) The cell viability in IM-9 cells treated with vehicle (DMSO) or the indicated concentrations of TC-S 7005 for 72 h ( n = 3). ( E ) Annexin V-positive/PI-negative IM-9 cells treated with vehicle (DMSO) or 10 muM of TC-S 7005 for 72 h ( n = 3). ( F , G ) The % components of cell-cycle phases and % cells in the G 2 /M phase in IM-9 cells treated with vehicle (DMSO) and 10 muM of TC-S 7005 for 72 h ( F ) or 10 muM of KIRA8 ( G ) for 24 h. For these experiments, four independent biological samples were used. ( H ) Quantitative RT-PCR of relative PLK2 mRNA levels in BM samples of control subjects ( n = 6) and patients with NDMM who attained a complete response receiving bortezomib-based treatment and high-dose melphalan ( n = 6). ( I ) The expression of PLK2 protein in the BM clot specimen of a patient with NDDM was confirmed by immunohistochemical analysis with anti-PLK